Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab

Guardado en:

Detalles Bibliográficos
Autores principales:	Alexander N Shoushtari, Katherine S Panageas, Jedd D Wolchok, Paul B Chapman, Margaret Callahan, Allison Betof Warner, Vetri Sudar Jayaprakasam
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c887a53451914cb28a74ca903b635a10
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c887a53451914cb28a74ca903b635a10
record_format	dspace
spelling	oai:doaj.org-article:c887a53451914cb28a74ca903b635a102021-12-02T09:00:06ZRisks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab10.1136/jitc-2021-0033952051-1426https://doaj.org/article/c887a53451914cb28a74ca903b635a102021-10-01T00:00:00Zhttps://jitc.bmj.com/content/9/10/e003395.fullhttps://doaj.org/toc/2051-1426Alexander N ShoushtariKatherine S PanageasJedd D WolchokPaul B ChapmanMargaret CallahanAllison Betof WarnerVetri Sudar JayaprakasamBMJ Publishing GrouparticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Alexander N Shoushtari Katherine S Panageas Jedd D Wolchok Paul B Chapman Margaret Callahan Allison Betof Warner Vetri Sudar Jayaprakasam Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
format	article
author	Alexander N Shoushtari Katherine S Panageas Jedd D Wolchok Paul B Chapman Margaret Callahan Allison Betof Warner Vetri Sudar Jayaprakasam
author_facet	Alexander N Shoushtari Katherine S Panageas Jedd D Wolchok Paul B Chapman Margaret Callahan Allison Betof Warner Vetri Sudar Jayaprakasam
author_sort	Alexander N Shoushtari
title	Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
title_short	Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
title_full	Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
title_fullStr	Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
title_full_unstemmed	Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
title_sort	risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
publisher	BMJ Publishing Group
publishDate	2021
url	https://doaj.org/article/c887a53451914cb28a74ca903b635a10
work_keys_str_mv	AT alexandernshoushtari risksandbenefitsofreinductionipilimumabnivolumabinmelanomapatientspreviouslytreatedwithipilimumabnivolumab AT katherinespanageas risksandbenefitsofreinductionipilimumabnivolumabinmelanomapatientspreviouslytreatedwithipilimumabnivolumab AT jedddwolchok risksandbenefitsofreinductionipilimumabnivolumabinmelanomapatientspreviouslytreatedwithipilimumabnivolumab AT paulbchapman risksandbenefitsofreinductionipilimumabnivolumabinmelanomapatientspreviouslytreatedwithipilimumabnivolumab AT margaretcallahan risksandbenefitsofreinductionipilimumabnivolumabinmelanomapatientspreviouslytreatedwithipilimumabnivolumab AT allisonbetofwarner risksandbenefitsofreinductionipilimumabnivolumabinmelanomapatientspreviouslytreatedwithipilimumabnivolumab AT vetrisudarjayaprakasam risksandbenefitsofreinductionipilimumabnivolumabinmelanomapatientspreviouslytreatedwithipilimumabnivolumab
_version_	1718398331706671104

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab

Ejemplares similares